Thu, Jan 29, 2015, 11:23 AM EST - U.S. Markets close in 4 hrs 37 mins

Recent

% | $
Quotes you view appear here for quick access.

Vical Incorporated Message Board

strawgold 37 posts  |  Last Activity: Dec 9, 2014 4:31 PM Member since: Dec 12, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • To Yahoo top personnel: I have a sensible suggestion. CLOSE DOWN ALL MESSAGE BOARDS. Only one person can use them, and you know you don't care anyway.

    I'm gone.

  • Reply to

    The Second Interview

    by callmesparkyman Dec 5, 2014 4:26 PM
    strawgold strawgold Dec 9, 2014 12:39 PM Flag

    The mad scientist who cloned Speez in the first test tube was baffled by the miraculous escape of the spores that spawned more of Speez. The slimy amoebas took notice of rejection; they seemed to thrive on it. Their advance behaved just like Mickey Mouse and the Sorcerer's Broom; the more it was attempted to smite them, the more they divided and multiplied. On they marched, sneering at Yahoo programmers. The Mega-Speez changed colors; from bright vomit orange to a "greyed out" version which was the most dangerous form of all - as it replicated itself thousand of times in a moment. The computers at Yahoo were all frozen under the onslaught, the programmers completely overwhelmed and undermanned. Rendered impotent. (to be continued)

  • Reply to

    A message for BigT-again - Collategene

    by strawgold Dec 6, 2014 12:16 PM
    strawgold strawgold Dec 7, 2014 9:47 AM Flag

    BigT: Thanks for a sane discussion
    and yes, I have Spezma on ignore, much good though it does.

    Nothing I could find really proved or disproved the patent issue and the website clearly states that a phase III trial is underway with a special protocol assessment - and that the 1&2 combo trial on lymphedemia expects to reveal results the last half of 2014, which is an undisputed date, obviously. So I contacted info at vocal. We'll see if they respond, which I expect they will.

    It's an important issue and it would be interesting to know for sure without going back through pages of fine print.

  • Reply to

    A message for BigT-again - Collategene

    by strawgold Dec 6, 2014 12:16 PM
    strawgold strawgold Dec 6, 2014 12:23 PM Flag

    P.S. on Collategene: Here is something more, dated Feb, 2012 - and remember, VICL also has interest in the ischemic limb issue.:

    start******The current pipeline for PAD is strong, with 43 molecules in various phases of clinical development. Due to there being no available option to treat CLI currently, most of the therapies in the pipeline are classified as FIC. includes potassium channel and chloride channel activators targeting Acute Limb Ischemia (ALI), which is the primary stage of PAD. The PAD therapeutic pipeline also includes autologous stem cell therapies and gene therapies targeting CLI. Ixmyelocel-T and Collategene are the two late-stage therapies which have received fast track designation. Thus, the strong PAD therapeutics pipeline indicates that in the future the PAD therapeutics market will witness the launch of various therapies with specific novel disease-modifying modes of action.******end

    I'm not saying I know anymore than what I read, but right now, it's active and in late stage development.

  • Bit T: I thought about your last post, since Collategene was clearly listed in the pipeline. I looked up as much as I could find on how the patents might be affected just in case I missed something. (and I STILL could have missed something) (we small investors are the last to find info)

    The "deal" could expire in 2020 but that is a long way off. Here is a snippet about the program and if I find more, I'll post it, but I don't think the patent is an issue right now:

    start *****The market is set to witness patent expiration of various drugs.

    However, the expected launch of novel first-in-class (FIC) therapies like autologous cell therapy (Ixmyelocel-T) and gene therapy (Collategene) in the late stage of forecast period and growing prevelance of disease would drive the PAD therapeutics market in the coming years.

    Collategene, a gene therapy was earlier filed in Japan but recently AngesMG Inc. has withdrawn its NDA filling and would conduct more clinical trials to further evaluate the results. Collategene is under preparation for Phase III trial in the US and EU and would start by the end of the fourth quarter of 2011. ******end

  • Reply to

    The Second Interview

    by callmesparkyman Dec 5, 2014 4:26 PM
    strawgold strawgold Dec 5, 2014 5:07 PM Flag

    Strange how the censors can immediately leap to act, but the programmers don't seem to get out of bed in the mornings for years and years.....

  • Reply to

    The Second Interview

    by callmesparkyman Dec 5, 2014 4:26 PM
    strawgold strawgold Dec 5, 2014 5:06 PM Flag

    Once upon a time in the hinterland of Nova, there was a large, stagnant pool of darkness known as Somes. Somes was teeming with life, and one of the lesser species was known as Speez. Speez was a crafty clone of several other species grown in the test tubes of an underground laboratory along the banks of the Somes..........

    (to be continued........)

  • Reply to

    Astellas and AnGes alliances reminders

    by strawgold Dec 5, 2014 12:49 PM
    strawgold strawgold Dec 5, 2014 3:03 PM Flag

    Unless you can post a link to the "lost patent" info, I tend to discount the source. The info I posted came from their website, with dates imminent, not stale dates. I don't believe that even if their website needs updating, that they would use these dates if they had patent disruption. That would be a disclosure item of magnitude.

    Try again.

  • Reply to

    Filtering spezma

    by bottom2up Dec 5, 2014 7:52 AM
    strawgold strawgold Dec 5, 2014 1:50 PM Flag

    Oh, man! An interview with our Main Man Applicant! Yes, bring it.

  • Reply to

    Astellas and AnGes alliances reminders

    by strawgold Dec 5, 2014 12:49 PM
    strawgold strawgold Dec 5, 2014 1:48 PM Flag

    t is in the pipeline. But it is being developed by AnGes, who are responsible for the trials, the set up with SPA and the data, under an alliance with Vical using their DNA biotechnologies. It is shown on the website as such.

  • Reply to

    Filtering spezma

    by bottom2up Dec 5, 2014 7:52 AM
    strawgold strawgold Dec 5, 2014 12:53 PM Flag

    Useless to try. Just keep bumping those posts you value or they will disappear into the abyss.

  • Reply to

    Censorship

    by callmesparkyman Dec 5, 2014 12:34 PM
    strawgold strawgold Dec 5, 2014 12:51 PM Flag

    Freedom of Speech only applies to those who abuse it, evidently. Keep the faith and keep bumping.

  • Asters Phase III This trial is also "still recruiting" patients, and the expected completion date is March 2017, still a long way off, and likely to be even longer as all patients data has to be considered - the trial was begun in 2013. Unless a miracle happens, no breath holding on this one.

    Collategene (angiogenesis, Critical limb ischemic disease) is in good position on starting the phase III trial under AnGes alliance, which is exciting, if I were still excitable, since ischemia is a very unmet need. AnGes has reached an agreement with the FDA for the Special Protocol Assessment, a binding agreement that keeps everyone honest when assessing the data endpoints. It also has "Fast Track" status, which doesn't mean much, I have found to my sorrow when enthusiasm overloaded my sense.

    AnGes is also underway with a phase 1/2 trial for Lymphedema, and THOSE results are expected in the last half of 2014. Which is NOW.

    If anyone wants to read this, be prepared to help me defend the post from the expected and immediate onslaught from the Clone that resides here.

  • Reply to

    Job Opening

    by callmesparkyman Dec 4, 2014 12:25 PM
    strawgold strawgold Dec 4, 2014 3:29 PM Flag

    I know. But we couldn't even follow sensible posters because of this nitwit filling the entire board with his "grey out" nonsense after being ignored. That's actually Yahoo's fault for not somehow programming it more effectively.

    I'm willing to let it drop. But if he PERSISTS, I'm ready to come back again with more for him. It's the only way.

  • Reply to

    Job Opening

    by callmesparkyman Dec 4, 2014 12:25 PM
    strawgold strawgold Dec 4, 2014 2:25 PM Flag

    Callme: Well, he wouldn't be much use there, that's for sure so that's out. Or in the cajones dept. either because he doesn't have any of those. But hark! I don't see any more messages from him so he must have filled the boiler position or gone elsewhere. Maybe to the Toilets#R#us board.

  • Reply to

    Job Opening

    by callmesparkyman Dec 4, 2014 12:25 PM
    strawgold strawgold Dec 4, 2014 1:57 PM Flag

    We are in receipt of Novaspeez/spas's outstanding resume and are doing our best.

    While we have no position to fit him presently above ground, we recognize this kind of talent when we see it, and have created a new position just for him. It's called "Upside Down - the New Vision" and it's located to the far right of the boiler room. We would have put his name(s) on the door, but we ran out of room.

    We also attempted to customize his desk but somebody keeps flushing it.

  • Reply to

    Job Opening

    by callmesparkyman Dec 4, 2014 12:25 PM
    strawgold strawgold Dec 4, 2014 1:26 PM Flag

    No, he sucks at message boarding. There must be a dept. further down in the basement or something.

  • Reply to

    Job Opening

    by callmesparkyman Dec 4, 2014 12:25 PM
    strawgold strawgold Dec 4, 2014 1:22 PM Flag

    He's already applied for the position since he feels fully qualified and you should see his resume......it's something to behold.

  • Reply to

    Global Investor Charles De Vaulx's

    by strawgold Dec 3, 2014 12:21 PM
    strawgold strawgold Dec 4, 2014 11:27 AM Flag

    I think he locks himself in one of Yahoo's restrooms on his breaks and types away. (I was going to say "bangs away" but decided it might be a poor choice of words) Nothing else explains why Yahoo's Mr. Fix it men can't rewrite the "ignore" feature to function correctly.

  • Reply to

    Just posted

    by j.britton88 Dec 3, 2014 3:59 PM
    strawgold strawgold Dec 3, 2014 8:04 PM Flag

    Tee hee hee! blip!

VICL
1.02-0.01(-0.97%)11:21 AMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.